Clinical research in resource-limited settings
IFPMA congratulates the Council for International Organizations of Medical Sciences (CIOMS) and the work of its technical working group for the very comprehensive report on Clinical research in resource-limited settings.
The biopharmaceutical industry is already actively engaged and contributes to the evolving clinical research ecosystem.
Read our perspective, which includes examples and case studies of how members contribute their expertise and knowledge to expand the clinical research infrastructure in LMICs.
Related news and resources
How we are contributing to global pharmaceutical standards
The evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...
Read more
The socio-economic value of adult immunisation programmes
Download this OHE report, commissioned by IFPMA, to learn more about the socio-economic value of adult vaccination programems on individual lives and societies at large.
Read more
Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda
On 9 April 2024, IFPMA, Interfarma, and FIFARMA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda. The letter is available for download in English, Portuguese, and Spanish.
Read more